Contact
Please use this form to send email to PR contact of this press release:
Immunomedics Strongly Encourages Stockholders to Reject the venBio Nominees — With Four New Independent Directors and a Robust Value-Maximization Process, Stockholders Should Not Risk Giving venBio Directors Control of the Immunomedics Board of…
TO: